Source comparison
Best BPC-157 Dosage for Tissue Repair: Injury Type Comparison
Injury severity and tissue type determine optimal BPC-157 dosing protocols. The table below compares dosing strategies across common injury categories based on published animal models and observational human protocols. Acute Tendon Rupture (Achilles, Rotator C
This comparison does not assign a generated winner or score.
- Injury severity and tissue type determine optimal BPC-157 dosing protocols. The table below compares dosing strategies across common injury categories based on published animal models and observational human protocols.
- Acute Tendon Rupture (Achilles, Rotator Cuff)
- 400–500 mcg twice daily
- Peri-injury SC/IM injection
- 14–21 days
- High-dose localised protocol accelerates collagen deposition during inflammatory phase. Reduce to 250 mcg twice daily for weeks 3–6 to prevent fibrotic scarring
- Chronic Tendinopathy (Tennis Elbow, Patellar)
- 200–300 mcg once daily
- Peri-injury SC injection
- 4–8 weeks
- Lower sustained dose promotes gradual ECM remodelling without triggering excessive inflammation. Avoid twice-daily dosing to reduce fibrosis risk
- Ligament Strain (MCL, ACL Partial Tear)
- 300–400 mcg twice daily
- 21–28 days
- Moderate dose supports ligament healing while minimising joint stiffness from excessive collagen cross-linking
- Muscle Strain (Hamstring, Quadriceps)
- 250–350 mcg twice daily
- IM injection into affected muscle
- 10–14 days
- Muscle tissue's higher vascular density allows lower doses than tendon injuries. Prioritise IM route for direct myofibril access
- Gastric Ulcer or Mucosal Damage
- 200–250 mcg once daily
- Systemic SC injection (abdomen)
- Gastric mucosa's dense capillary network requires only systemic dosing. Localised injection offers no benefit and increases injection site discomfort